Erectile dysfunction (ED) is a deceptively simple diagnosis. To the patient, it manifests as the inability to achieve or maintain an erection. To the clinician, however, it represents an intricate web of neurovascular mechanisms, endocrine signals, psychological influences, and endothelial function. One may call ED a disorder of erection, but in truth it is a disorder of systems.

Phosphodiesterase type-5 (PDE5) inhibitors—particularly tadalafil—remain the cornerstone of therapy for male sexual dysfunction. Yet even this modern pharmacologic triumph reveals its limitations: not all men respond to tadalafil, and not all responders reach the same therapeutic peak. Predicting who will benefit, who will fail, and who may permanently recover erectile function after treatment has become an increasingly relevant clinical question.

The study that forms the basis of this review investigates the fascinating arena of prediction in ED therapy. By combining nocturnal penile tumescence and rigidity testing (NPTR), audiovisual sexual stimulation (AVSS), and detailed neurovascular metrics, the researchers attempt to discern early markers that differentiate tadalafil responders from non-responders. In essence, the study asks: Can we identify who will respond to tadalafil before we prescribe it?

The answer, as we shall see, is both clinically enlightening and profoundly practical.

Understanding the Physiological Background: Why Prediction Matters

The quest to predict tadalafil responsiveness is not merely academic curiosity. PDE5 inhibitors work by enhancing nitric oxide–mediated vasodilation in penile cavernosal smooth muscle—a mechanism that requires intact neural input, healthy endothelium, functional smooth muscle, and psychological readiness. If any component of this chain fractures, tadalafil’s efficacy falters.

ED stems from multiple etiologies: vascular insufficiency, impaired cavernosal smooth muscle relaxation, neurogenic dysfunction, psychogenic inhibition, endocrine imbalance, or a combination of these. When clinicians prescribe tadalafil, they often do so empirically, assuming the mechanism of dysfunction will respond similarly across patients. Yet anyone who has treated ED knows this is not true.

Predictive markers serve three important purposes:

they reduce unnecessary medication exposure in likely non-responders;
they guide alternative therapies (e.g., low-intensity shockwave therapy, intracavernosal injections, hormonal therapy);
they allow clinicians to counsel patients more realistically regarding prognosis.

Therefore, identifying predictive parameters is a pursuit rooted not only in scientific curiosity but also in clinical efficiency and personalized medicine.

This study proposes that NPTR parameters and AVSS-induced rigidity patterns may provide the diagnostic insight needed to forecast therapeutic outcomes.

Study Overview and Methodological Framework

The research enrolled 111 men aged 18–65 with erectile dysfunction lasting more than six months. All were sexually active, in stable relationships, and sufficiently motivated to undergo detailed psychosexual testing—an inclusion criterion that, in itself, filters for a compliant and engaged cohort.

The study design reflects a deep appreciation of ED pathophysiology:

Baseline evaluation included medical history, hormonal profiling, and neurologic assessment.
Penile Doppler ultrasonography measured peak systolic velocity (PSV), end-diastolic velocity (EDV), and resistive index (RI).
NPTR testing used RigiScan Plus to record nocturnal erectile episodes.
AVSS testing stimulated erections under controlled erotic exposure to measure rigidity in the erectogenic environment.

Patients then began tadalafil 5 mg daily for three months, followed by classification into:

Group A: tadalafil responders
Group B: tadalafil non-responders

Responders were defined according to standardized IIEF-EF improvements and real-world sexual activity outcomes.

The researchers then compared NPTR and AVSS parameters between groups, seeking patterns that predicted success or failure.

This multifaceted methodology is one of the study’s strengths. It integrates physiologic, psychogenic, and vascular determinants into a unified predictive model.

NPTR: The Nighttime Window Into Erectile Physiology

Nocturnal penile tumescence and rigidity testing remains a gold standard for distinguishing psychogenic from organic ED. Men with normal NPTR typically possess intact neurovascular function, suggesting that daytime dysfunction may stem from psychological inhibition rather than physiologic impairment.

Key NPTR parameters include:

number of tumescence episodes
number of rigidity episodes
maximal tip rigidity
maximal base rigidity
duration of rigidity ≥60%
tumescence activity units (TAU)

In this study, NPTR emerged as a powerful predictor of tadalafil responsiveness.

1. Responders exhibited significantly higher nocturnal rigidity at baseline.

Men who later responded to tadalafil had notably better:

tip rigidity during erections,
base rigidity,
duration of rigid episodes,
and total rigidity activity.

This suggests that tadalafil, which amplifies an already functioning nitric oxide pathway, works best in men whose erectile circuitry is largely intact.

2. Non-responders had reduced nocturnal rigidity despite erotic stimulation.

This finding may reflect deeper structural compromises:

cavernous fibrosis,
smooth muscle apoptosis,
or severe endothelial dysfunction.

In these men, tadalafil’s mechanism cannot compensate for the underlying deficit.

3. The most predictive NPTR parameter was duration of rigidity ≥60%.

This threshold correlates with erections sufficient for penetration. If nocturnal erections cannot sustain 60% rigidity, the odds of tadalafil success drop dramatically.

Altogether, NPTR serves not merely as a diagnostic tool but as an early indicator of PDE5 inhibitor response.

AVSS: What Erotic Stimulation Reveals About Daytime Function

While NPTR reflects spontaneous nocturnal erections, AVSS reflects performance under sexually arousing conditions. The RigiScan assessment during erotic stimuli measures:

latency to erection onset
rigidity response
plateau duration
maximal rigidity achieved

AVSS results complement NPTR by assessing psychogenic influences and situational erectile performance.

1. Tadalafil responders achieved higher rigidity under AVSS.

Responders showed:

faster onset of erection,
higher maximal rigidity,
and longer maintenance of rigidity.

These differences highlight the role of psychogenic and hemodynamic synergy. Men whose erections respond robustly to erotic cues benefit more from PDE5 inhibitors.

2. Non-responders exhibited “flat curves” with minimal response to stimulation.

These patients may suffer from:

neurogenic impairment,
advanced vasculopathy,
or poor cavernosal compliance.

Notably, a subdued AVSS response strongly predicted tadalafil failure.

3. Combining NPTR and AVSS increased predictive accuracy.

The study found that men with both poor NPTR and poor AVSS responses were almost universally non-responders. Conversely, strong responses in both modalities predicted high success rates with tadalafil.

This combined diagnostic approach may serve as a valuable tool for clinicians navigating complex ED cases.

Hemodynamic Predictors: The Role of Penile Doppler Parameters

Although NPTR and AVSS dominated predictive value, penile Doppler findings contributed additional nuance.

Responders typically demonstrated:

higher PSV, indicating adequate arterial inflow
lower EDV, suggesting efficient venous occlusion
higher resistive index (RI), reflecting less venous leakage

Men with abnormal Doppler findings—particularly those with veno-occlusive dysfunction—were far less likely to respond to tadalafil.

This aligns with established physiology: tadalafil cannot correct venous leakage, and its efficacy diminishes sharply when inflow fails to generate sufficient intracavernous pressure.

Thus, Doppler metrics provide a vascular anchor to the neurophysiologic insights provided by NPTR and AVSS.

The Predictive Model: Bringing the Findings Together

The study’s central outcome is the identification of a predictive framework. The most accurate predictors of tadalafil responsiveness included:

NPTR duration of rigidity ≥60%
NPTR tip and base rigidity
AVSS maximum rigidity response
PSV and RI values on Doppler
Presence of spontaneous erections

From a clinical perspective, this allows practitioners to stratify patients into three categories:

1. High-likelihood responders

Men with:

preserved NPTR
robust AVSS responses
normal Doppler profiles

These patients benefit most from tadalafil.

2. Intermediate-likelihood responders

Men with:

partial deficits in NPTR or AVSS
borderline Doppler values

These patients may respond but require close monitoring and adjunctive interventions.

3. Low-likelihood responders

Men with:

absent nocturnal rigidity
minimal erotic-stimulated response
significant veno-occlusive dysfunction

These patients benefit more from alternative therapies than from escalating tadalafil doses.

This predictive model transforms tadalafil from a one-size-fits-all medication into a tailored therapy informed by physiological data.

Clinical Significance: Why These Findings Matter Today

The implications of this study ripple through several dimensions of ED management:

1. Personalized medicine becomes achievable.

Rather than prescribing tadalafil to every patient with ED, clinicians can:

reserve tadalafil for physiologically appropriate candidates;
redirect non-responders early to second-line therapies.

This saves time, reduces frustration, and increases treatment satisfaction.

2. Health economics improve.

Predicting tadalafil failure before months of ineffective therapy reduces cost burden for both patient and healthcare system.

3. Psychological outcomes are better.

Men who fail tadalafil often blame themselves, deepening psychogenic stress. Predicting failure upfront reframes the issue as physiology, not personal failure.

4. The role of NPTR and AVSS testing strengthens.

These tools, historically underutilized, regain importance in precision ED therapy.

A Word on Long-Term Cure: Can Predictive Markers Forecast Recovery?

Interestingly, the authors explored whether responders—particularly those with strong NPTR—achieved long-term restoration of function after discontinuing tadalafil.

Preliminary findings suggest:

men with robust NPTR and AVSS responses before treatment
and strong tadalafil response during treatment

were more likely to maintain improved erectile function even after tadalafil cessation.

This implies partial reversal of underlying endothelial dysfunction—a tantalizing, though still speculative, concept.

Conclusion

Predicting response to tadalafil is no longer an aspirational goal but an achievable, evidence-based process. By integrating NPTR, AVSS, and penile Doppler parameters, clinicians can identify which men will benefit from therapy, which require alternative strategies, and which may experience long-term improvement beyond pharmacologic dependence.

This diagnostic triad reveals a core truth of ED therapy: successful treatment is less about amplifying nitric oxide, and more about understanding the vascular, neural, and psychological frameworks into which the drug is introduced.

Tadalafil remains an excellent medication—but only when the biological stage is properly set.

FAQ

1. Can NPTR really predict tadalafil response with high accuracy?

Yes. NPTR parameters—especially duration of rigidity ≥60%—strongly correlate with tadalafil success. Men with preserved nocturnal erections nearly always respond well.

2. What does it mean if AVSS shows weak rigidity but NPTR is normal?

This pattern suggests psychogenic ED. These men typically respond well to tadalafil when combined with counseling or sexual therapy.

3. Should all patients undergo NPTR and AVSS before tadalafil therapy?

Not necessarily. These tests are most useful for complex cases, treatment failures, or men with strong suspicion of organic ED. They are not required for straightforward cases.